Business context and reporting period
The supplied filing is CopyTele, Inc.’s unaudited Form 10-Q for the quarter and six months ended April 30, 2014—not an Anixa Biosciences filing. CopyTele’s business centered on acquiring, licensing, and enforcing patent portfolios. During the quarter it signed five revenue-producing license or settlement agreements related to web-conferencing encryption and J-Channel window-frame patents. The company reported nine revenue-producing agreements since launching its patent-monetization model in January 2013, with 33 patent-infringement lawsuits still pending.
Financial results and liquidity
| Metric | Three months ended April 30, 2014 | Six months ended April 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $1.105 million | $1.105 million | $0 |
| Operating expenses | $2.460 million | $4.425 million | $1.851 million / $3.924 million |
| Operating loss | $1.355 million | $3.320 million | $1.851 million / $3.924 million |
| Net loss | $3.249 million | $6.864 million | $2.476 million / $4.571 million |
| Basic and diluted loss per share | $0.02 | $0.03 | $0.01 / $0.02 |
| Cash used in operating activities | Six-month total: $1.680 million | $1.803 million |
All reported revenue came from five one-time lump-sum licenses or settlements and was recognized upon execution. Inventor royalties and contingent legal fees were about $465,000. The filing does not report a gross margin measure. The six-month net loss included a $2.311 million loss from changes in derivative-liability fair value and a $483,000 loss on extinguishment of debt; these non-operating charges materially affected reported results.
At April 30, 2014, cash and cash equivalents were $618,000 and short-term certificates of deposit were $2.050 million. Accounts receivable were $828,000, and total current assets were $3.630 million versus current liabilities of $10.682 million. Shareholders’ deficiency was $4.846 million. Cash, cash equivalents, and short-term investments totaled about $2.668 million, up about $1.770 million from October 31, 2013. Six-month investing cash outflow was $2.051 million, primarily reflecting certificate-of-deposit purchases; financing provided $3.451 million, mainly from a $3.5 million debenture issuance.
Debt and obligations included a $5.0 million related-party loan payable, a November 2016 convertible debenture with $3.5 million face value ($1.627 million net of discount), a $2.750 million derivative liability, and a $3.037 million patent-acquisition obligation. The contractual-obligations table lists $11.624 million in total obligations, including the related-party loan and patent obligation. A subsidiary’s $5.0 million loan from Mars Overseas Limited is secured by Videocon GDRs valued at about $3.977 million; if unpaid when due, those securities may be surrendered.
Changes versus prior comparable periods
- Revenue rose from zero to $1.105 million in both the quarter and six-month period, but did not cover operating expenses.
- Six-month operating loss narrowed by about $604,000, while net loss increased by about $2.292 million. The increase reflected, in particular, a swing from a $210,000 derivative-liability gain to a $2.311 million loss, plus the debt-extinguishment charge.
- Six-month G&A declined about $213,000 to $3.704 million, but included $1.877 million of non-cash stock-option compensation, up from $1.455 million.
- The company issued a $3.5 million 6% convertible debenture in November 2013. In the quarter, $1.240 million principal of earlier 8% debentures converted into shares and $200,000 was repaid; the earlier debentures were extinguished in full.
- Common shares outstanding increased to 219.4 million at April 30, from 209.3 million at October 31, 2013. The filing reported 220.4 million shares outstanding on June 10, 2014.
Outlook, risks, contingencies, and unusual items
Management believed available cash, short-term investments, receivables, and expected licensing and enforcement proceeds would fund operations for at least 12 months. It cautioned that forecasts may differ from actual results, future funding may not be available on favorable terms or at all, and insufficient funding or inability to reduce costs could force the company to curtail or cease operations. Additional equity or convertible-debt financing could dilute shareholders; the company also gave no assurance it could repay outstanding debt.
CopyTele expected most of the $828,000 receivable and $483,000 of royalties and contingent legal fees payable to be collected or paid in the third quarter of fiscal 2014. Its Aspire Capital agreement permitted up to $10 million of stock purchases over two years, subject to price and other conditions; no shares were sold under it in the six months ended April 30, 2014.
The company’s AUO/E Ink litigation sought damages for alleged contract and other violations. CopyTele said it might not prevail in arbitration and could be liable for AUO’s attorneys’ fees, potentially exceeding $1 million. Patent-enforcement actions also carry potential sanctions or attorneys’ fees. The company reported no material change in the risk factors from its prior annual report. Its Videocon investment was exposed to share-price and foreign-exchange risk; a hypothetical 10% adverse move in both was estimated to reduce fair value by about $398,000.
Important facts for investors to verify
- Confirm the issuer: this source is CopyTele, Inc., not Anixa Biosciences Inc.
- Assess whether one-time patent settlements can recur and whether licensing receipts can support ongoing operating and litigation costs.
- Review the $5.0 million related-party loan’s maturity, security, repayment source, and relationship to the Videocon GDR collateral.
- Evaluate the convertible debenture’s conversion terms, derivative valuation, potential dilution, and the effects of further stock-price changes.
- Check collection of receivables, payment of royalties and contingent fees, and availability and terms of any Aspire Capital or other financing.
- Track the AUO/E Ink matter, possible fee exposure, and the status and economics of the 33 pending patent lawsuits.